Aptevo Therapeutics Inc. (APVO)

Aptevo Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	-	-	3.11	12.29
Revenue Growth (YoY)	-	-	-	-	-74.67%	185.26%
Gross Profit	-	-	-	-	3.11	12.29
Selling, General & Admin	11.84	11.77	10.22	11.77	13.87	14.7
Research & Development	14.83	14.54	14.38	17.11	17.88	18.99
Total Operating Expenses	26.67	26.31	24.6	28.88	31.76	33.69
Operating Income	-26.67	-26.31	-24.6	-28.88	-28.64	-21.4
Total Non-Operating Income (Expense)	0.41	0.35	0.47	10.23	35.66	-8.01
Pretax Income	-26.26	-25.97	-24.13	-17.41	8.03	-28.46
Net Income	-27.92	-27.54	-24.13	-34.82	16.05	-56.91
Minority Interest in Earnings	1.67	1.57	-	-	-	-
Earnings From Discontinued Operations	-	-	-	1.24	1.01	0.95
Net Income to Common	-27.92	-27.54	-24.13	-34.82	16.05	-56.91
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change (YoY)	3745.29%	41038.85%	8709.15%	-	8.85%	38.25%
EPS (Basic)	-79.52	-87.27	-31460.20	-870550.00	808790.00	-3674720.00
EPS (Diluted)	-79.52	-87.27	-31460.20	-870550.00	802930.00	-3674720.00
Shares Outstanding	1.2	1	0	0	0	0
Free Cash Flow	-26.98	-25.59	-23.79	-11.73	-21.05	-22.39
Free Cash Flow Per Share	-61.02	-81.11	-31010.40	-1347210.00	-2417750.00	-2799410.00
Gross Margin	-	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-	-919.75%	-174.10%
Profit Margin	-	-	-	-	483.01%	-470.75%
FCF Margin	-	-	-	-	-676.01%	-182.17%
EBITDA	-26.46	-26.07	-24.25	-28.31	-27.74	-20.26
EBITDA Margin	-	-	-	-	-890.82%	-164.79%
EBIT	-26.67	-26.31	-24.6	-28.88	-28.64	-21.4
EBIT Margin	-	-	-	-	-919.75%	-174.10%

Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q